Schrödinger, Inc. reports developments tied to its computational platform for molecular discovery, which is licensed to biotechnology, pharmaceutical, industrial and academic customers for drug development and materials design. Company updates commonly cover Software segment performance, hosted and license-server delivery, annual contract value, and the role of software revenue in the business.
News also addresses Schrödinger's Drug Discovery segment, including collaborative and internal programs, together with clinical or regulatory disclosures when applicable. Recurring corporate items include quarterly and annual financial results, investor conference participation, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), shareholder voting matters, governance changes and capital-structure disclosures.
Schrödinger (SDGR) raised its full-year 2026 outlook after reporting third-quarter revenue of $64.5 million, up 19% year over year. Annual contract value, a software contract billing metric, rose 17% to $44.7 million. Software revenue increased 6% to $38.2 million, while drug discovery revenue reached $24.2 million versus $13.0 million, primarily reflecting a Structure Therapeutics milestone.
Net loss widened to $37.7 million from $32.8 million despite operating expenses falling 13% to $64.4 million. Software gross margin was 75%, down from the prior year as hosted licensing expanded. Cash, restricted cash and marketable securities totaled $373 million. The company expects 2026 annual contract value of $222 million–$232 million, up from $218 million–$228 million, and drug discovery revenue of $75 million–$85 million, up from $65 million–$75 million. It expects operating expenses below 2025.
Schrödinger (Nasdaq: SDGR) management will participate in a fireside chat at the UBS Global Healthcare Conference on November 10, 2026. The live presentation begins at 9:30 a.m. E.T. A webcast will be available in the Investors section of the company’s website and archived for approximately 90 days following the event.
Schrödinger (SDGR) granted restricted stock units covering 5,716 common shares on October 21, 2026, to five newly hired employees.
The awards were employment inducements under the 2021 Inducement Equity Incentive Plan and Nasdaq Listing Rule 5635(c)(4), approved by the board’s compensation committee under delegated authority. The units vest over four years: 25 percent after 12 months of continuous service from the vesting commencement date, followed by equal yearly installments of one-quarter of the original award over the next three years. The grants remain subject to the award agreements and the plan.
Schrödinger (Nasdaq: SDGR) will report its third quarter 2026 financial results on November 4, 2026, after financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The webcast will be available in the Investors section of its website and archived for approximately 90 days following the event.
Schrödinger (SDGR) announced research published in Nature identifying multi-lithium ion clusters in common lithium-ion battery electrolytes through simulations and experiments.
The study, conducted with Columbia University and the New York Structural Biology Center, found that up to 40% of lithium ions form clusters without anions, or negatively charged ions. Clustering becomes more prevalent at higher salt concentrations. Simulations using Schrödinger’s machine learning technology agreed with experimental measurements. Quantum chemical calculations suggest these clusters help form the solid electrolyte interphase, a protective film on the battery anode. The company sees potential for the findings to guide electrolyte design toward improved battery performance.
Schrödinger (SDGR) granted restricted stock units covering 2,243 shares of common stock to three newly hired employees on September 13, 2026.
The awards were issued under the company’s 2021 Inducement Equity Incentive Plan and approved by the compensation committee as a material inducement to employment in line with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years: 25% after 12 months of continuous service from the vesting commencement date, with the remaining 75% vesting in three equal annual installments upon completion of each additional year of service. The grants remain subject to the terms of individual award agreements and the 2021 Inducement Equity Incentive Plan.
Schrödinger (SDGR) co-founded Tectora Therapeutics with New Enterprise Associates and RA Capital Management and licensed two early-stage immunology and inflammation programs to the new company.
Tectora concurrently closed a $55 million Series A investment from NEA and RA Capital. Schrödinger contributed small-molecule programs SDGR-4594 and SDGR-8139 in exchange for an equity stake in Tectora and eligibility for future milestones and royalties. Tectora will collaborate with Schrödinger’s drug discovery team and use Schrödinger’s computational platform at scale to advance these programs toward clinical candidates. Schrödinger highlights that similar partnerships, including Nimbus, Morphic, Structure and Ajax, have together generated over $750 million in proceeds to the company.
Schrödinger (Nasdaq: SDGR) announced that its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation is scheduled for Monday, September 14, 2026 at 1:05 p.m. E.T. and will be available via live webcast in the Investors section of Schrödinger’s website, with an archive accessible for approximately 90 days.
Schrödinger (Nasdaq: SDGR) granted restricted stock units covering 3,315 common shares on August 12, 2026 to two newly hired employees under its 2021 Inducement Equity Incentive Plan. The RSUs serve as a material inducement to employment and vest over four years, subject to continuous service and plan terms.
Schrödinger (Nasdaq: SDGR) reported second quarter 2026 ACV of $29.6 million, up 27% year over year and $208 million on a trailing four-quarter basis. ACV excluding contribution was $22.6 million, up 23%. Total revenue rose 8% to $58.9 million, with software revenue of $32.5 million (down 10%) and drug discovery revenue of $23.0 million, reflecting a $10 million collaboration milestone tied to the Ajax Therapeutics acquisition. Contribution revenue was $3.4 million. Software gross margin was 71%, operating expenses declined 6% to $74.0 million, and other income reached $48.9 million, largely from Eli Lilly’s acquisition of Ajax Therapeutics.
Net income was $6.0 million versus a $43.2 million loss a year earlier, and cash, cash equivalents, restricted cash and marketable securities totaled $418.8 million. For 2026, Schrödinger expects ACV of $218–$228 million (10–15% growth) and raised drug discovery revenue guidance to $65–$75 million. The company launched early access to Bunsen, its agentic AI co-scientist, signed a Bunsen-focused software agreement with Bristol Myers Squibb, and entered a global discovery collaboration with Simcere, alongside publishing new validation research for its FEP+ and cryptic-binding-site workflows.